Merck Acquires WuXi Biologics’ Irish Vaccine Facility in $500M Deal

Acquisition Details:
Merck (known as MSD outside North America) has acquired WuXi Biologics' vaccine manufacturing facility in Dundalk, Ireland, for approximately $500 million125.

Facility Overview:
The 15,520-square-meter facility features drug substance and drug product manufacturing, as well as quality control labs for the supply of vaccine products for the global market12.

Employment Impact:
The facility currently employs approximately 200 professionals, with plans to add 150 new jobs1.

Handover Timeline:
The official handover of the facility is expected to be completed in the first half of 2025125.

Strategic Expansion:
This acquisition brings Merck's footprint in Ireland to eight locations, with over 3,000 employees across the country2.

Background Context:
The sale comes amidst potential U.S. legislation (BIOSECURE Act) that could restrict business for Chinese biotechnology companies, including WuXi Biologics14.

Sources:

1. https://www.pharmamanufacturing.com/industry-news/news/55253022/chinas-wuxi-biologics-sells-irish-vaccine-facility-to-merck-for-500m

2. https://www.chemanager-online.com/en/news/merck-co-acquires-vaccine-site-ireland-wuxi

4. https://www.bioprocessintl.com/facilities-capacity/merck-co-buying-own-dedicated-wuxi-vaccine-plant-for-500m-

5. https://s.yimg.com/ny/api/res/1.2/x93jyVmrMctwH7Jo7sgkWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQwMA--/https:/media.zenfs.com/en/dpainternational526/75601ad2b52cba89504b3af9e92a3f04?sa=X&ved=2ahUKEwivnuVnOaKAxWaJzQIHT6iKeIQB16BAgLEAI